Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses the role of the JAK-STAT pathway in autoimmune skin diseases and suggests potential therapeutic benefits of JAK inhibitors, but reports no new experimental results.

This study found that Israeli patients with alopecia areata had a higher prevalence of comorbid conditions, including food allergies and chronic spontaneous urticaria, compared to matched controls.

This review highlights the emerging role of long non-coding RNAs (lncRNAs) in dermatology, suggesting that lncRNAs significantly impact signaling pathways involved in normal skin functions and skin diseases, offering potential as biomarkers and therapeutic targets.

This review summarizes recent advances in nanomedicine-based therapies for psoriasis, highlighting their potential to provide targeted and sustained therapeutic effects by modulating key cellular components and signaling pathways involved in the disease, offering novel perspectives for future treatment development.

In this mini-review, recent insights suggest a possible role of type-2-related immunity in diseases like alopecia areata, vitiligo, and localized scleroderma, though whether this immune response benefits or worsens these conditions remains unclear.

In this study, infants born to mothers with alopecia areata had a higher risk of adverse birth outcomes, including preterm birth, low birth weight, Caesarean section, and congenital malformations.

Apremilast was not effective in treating moderate-to-severe alopecia areata.

This study observed initial hair regrowth in a businessman with alopecia areata universalis treated with tofacitinib, but the effect diminished, leading to renewed hair loss.

This review summarizes recent research on alopecia areata, highlighting advances in targeted therapies due to improved understanding of its immunopathogenesis, though it reports no new clinical results.

This study found that elevated serum levels of IL-15 in active alopecia areata patients are correlated with disease severity, suggesting it plays a role in disease pathogenesis.

This review discusses the mechanisms underlying immune tolerance failure in alopecia areata and highlights potential therapeutic avenues for restoring hair growth and achieving sustained remission, but reports no new clinical results.

This review identifies cysteine's central role in hair growth and its potential impact on Alopecia Areata's pathogenesis, suggesting examination of cysteine metabolism might clarify the disease's underlying mechanisms and lead to new treatments.

This review discusses the use of phosphodiesterase inhibitors for alopecia, finding promising preliminary results with topical caffeine for androgenetic alopecia and telogen effluvium, but limited success in alopecia areata.

This article reviews the role of the JAK-STAT pathway in inflammatory skin diseases and considers the therapeutic benefits of JAK inhibitors, presenting them as promising treatments but reports no new experimental results.

This case study reports a young male with alopecia universalis experienced significant hair whitening following baricitinib treatment, highlighting the need for further research on JAK inhibitors' impact on hair pigmentation and their underlying mechanisms.

This study found that patients with alopecia areata had increased levels of serum immunoglobulin E and interleukin-13 compared to healthy controls, with additional variation in levels observed across age and weight.

This case study reports the first known instance of lichen planopilaris being associated with multiple autoimmune syndrome in a woman with hypothyroidism and Crohn's disease.

This review discusses how the skin microbiome impacts different types of cutaneous wounds, such as acute and chronic, and explores therapeutic strategies targeting the microbiome to enhance healing outcomes.

This study observed mixed responses to dupilumab in patients with both atopic dermatitis and alopecia areata, suggesting a potential role for Th2 axis dysregulation in alopecia areata.

In this study, 25% of CCHCR1-deficient mice exposed to stress developed hair loss similar to human alopecia areata, suggesting CCHCR1 is a susceptibility gene for the disease.

This review discusses the pathophysiology of sleep disturbance in children with atopic dermatitis and highlights the need for further research on management strategies, but provides no new clinical results.

This review discusses the mechanisms of hair repigmentation and reports no clinical results; the authors suggest further research into topical treatments for reversing gray hair.

This review discusses recent advancements in nanotechnology for treating hypertrophic scarring and atopic dermatitis, highlighting the potential of nanotherapeutic platforms in enhancing therapeutic effects by modulating the skin's microenvironment.

This review discusses the molecular mechanisms and therapeutic effectiveness of Janus Kinase Inhibitors for inflammatory skin diseases, suggesting these inhibitors have a rapid onset and favorable safety profile compared to conventional treatments.

This study explores the potential of platelet-rich plasma (PRP) as a novel adjuvant therapy for eczema, positing that it may alleviate inflammation, enhance skin barrier function, and reduce recurrence.

In this study, botulinum toxin type A injections reduced the severity of treatment-resistant scalp psoriasis in more patients compared to placebo over a 12-week period.

This study found that feeding aged mice a probiotic yogurt induced changes leading to thicker, healthier fur, suggesting a bacteria-triggered interleukin-10-dependent mechanism that mimics signs of youth and reproductive fitness.

This review discusses the impact of sleep cycles and circadian rhythms on nighttime exacerbation of atopic dermatitis in children and presents potential treatment options for related sleep disturbances, but reports no new clinical results.

This review discusses recent advances and ongoing clinical trials in novel therapeutics for alopecia areata, despite the lack of current FDA-approved treatments for severe cases, and reports no new results.

This case report describes a patient who developed alopecia after 18 weeks of treatment with dupilumab for atopic dermatitis.